Re: : Another Dodo Everyone loves a ramp.. in and out like the SAS
Re: : Another Dodo got some ripley or are you just saying ?
Re: : Another Dodo Never seen anything ramped like this shard, beaufort, and phophets all e-maling me yesterday !!!!
Re: Stifel broker note: Target 60p looking good for take off here. bought some more yesterday morning. good luck to all that have been here since fastnet days. A gamble holding but it seems, subject to successful stage 3 trials, we will be rewarded handsomely
Stifel broker note: Target 60p Stifel broker note:Report card – an impressive first year Amryt Pharma is a specialty pharma company focused on acquiring, developing and commercialising drugs for the treatment of rare and orphan diseases. The company has had a frenetic first year as a public company. Having acquired two orphan drug development assets (Episalvan and AP102) in April 2016, the company went on to obtain European rights to Lojuxta to treat HoFH, a rare and fatal genetic disease, as well as securing a preferential €20 million EIB loan to fund future developments. With an encouraging start to Lojuxta sales, we recently added the product to our valuation of Amryt. Our 60p target price reflects the substantial upside opportunity we believe Amryt offers investors. Reiterate Buy.Phase III trial of Episalvan in epidermolysis bullosa (EB) pending. In March 2017, Amryt reached agreement with the FDA and EMA to a single pivotal trial design for a Phase III trial of Episalvan in EB. The blinded trial is expected to recruit 164 evaluable patients who will be treated for 90 days. The primary endpoint of the trial will be the proportion of patients with completely healed target wounds within 45 days. Secondary endpoints include time to wound healing and changes in pain and itch. An interim efficacy analysis, likely to occur in 1Q18, will be conducted after half the patients are recruited. Results from the trial are expected in 2H18. Thirty clinical sites in 15 countries have already been pre-qualified to participate in the study.We forecast sales of Episalvan in EB of $258 million by 2023 with launch in 2019. With around 55,000 sufferers in the US and Europe, EB represents a significant orphan drug condition with no current treatment other than regular bandaging. The genetic disorder is life threatening and represents an area of high unmet medical need.Lojuxta brings Amryt a commercial asset with growing sales. In December 2016, Amryt secured European commercial rights from Novelion Therapeutics Inc. to Lojuxta, an approved drug for the treatment of homozygous familial hypercholesterolaemia (HoFH), a rare and fatal genetic disease that results in extreme elevated cholesterol levels in the blood and formation of cholesterol deposits. In March 2017, Amryt announced Lojuxta sales achieved an annual run-rate of €10.5 million in its first three months. The company expects the product to be immediately self-funding.Reiterate Buy. We recently raised our target price reflecting our first time inclusion of Lojuxta in our valuation. Our target price is based on a hybrid of NPV, comparative and discounted revenue multiple methodologies. Our target price at 60p per share implies significant upside potential to the current share price.
from proactiveinvestor Amryt Pharma (‘Amryt’, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, yesterday announced the appointment of new Chief Commercial Officer (non-board), David Allmond, effective from 3 April 2017. Mr. Allmond has over 20 years' experience in the pharmaceutical industry in commercial roles. He joins the Company from Aegerion Pharmaceuticals (subsidiary of Novelion Therapeutics) where he was President of EMEA and, in particular, involved in the commercialisation of Lojuxta (lomitapide), the drug used to treat Homozygous Familial Hypercholesterolemia (‘HoFH’, approved in the EU since 2013. Amryt acquired the exclusive rights to sell Lojuxta across the EU, MENA (Middle East and North Africa), Turkey and Israel in December 2016. Prior to Aegerion, Mr. Allmond was Corporate Vice President of Global Marketing for Celgene Corporation where he was responsible for EMEA marketing and market access within Celgene. Prior to Celgene, he was Director of Sales and Marketing Effectiveness at Amgen Ltd. Amryt’s CEO, Joe Wiley, commented “We are pleased to welcome David to Amryt. David will resume control of the Lojuxta team and is the ideal person to take on responsibility for the commercial development of this business. We remain very excited about the potential to increase the numbers of patients on treatment in existing markets and also to open new markets within our territories”. Amryt is expected to announce its full year result on 30 March 2017.Our view: Building out the key management team to meet its commercial opportunities. This is a key appointment, as the new CCO was involved in the commercialisation of Lojuxta at Aegerion. Mr. Allmond, together with Amryt’s Chief Medical Officer, Dr. Mark Sumeray (previously a Chief Medical Officer at Aegerion led the clinical development and regulatory approval of the drug), will significantly boost the knowledge and accelerate commercial development of Lojuxta through building further commercial, medical and regulatory infrastructure necessary to support sales expansion. HoFH is a very rare, genetic disorder which starts in utero and causes premature cardiovascular disease. Historically, HoFH was estimated to occur in about 1 in 1 million people worldwide, but more recent studies suggest it may affect up to 1 in 300,000 people. The Group’s total licensed market for Lojuxta for HoFH indication is estimated at €50m and in Q3 2016, Aegerion generated US$22m in net product sales of lomitapide, of which, 15% was from prescriptions written outside of the US. Of this, 30% comes from Brazil and 70% was from the territories now being licensed to Amryt. With currently available treatment showing limited efficacy for some patients in controlling their LDL cholesterol (“bad” cholesterol) levels, there is significant potential for the Lojuxta to become a mainstay treatment for patients, having showed a 40-50% reduction in LDL cholesterol at 26 weeks after dosage during Phase 3 clinical trial, following which it remained stable at 126 weeks. Successful commercialisation Lojuxta will enables Amryt to generate material cash flows, while completing a further step toward its transformation into a fully-integrated sustainable and, commercial pharmaceutical Company. Beaufort considers Amryt to be significantly undervalued on the basis of commercial opportunity, prospective cashflow and peer group comparison and retains a Speculative Buy rating on the shares.
Re: Shore Capital value AMYT at 88p sp the start of he rise.....up 9.76%.....plenty more upside to come.
Re: Shore Capital value AMYT at 88p sp A very positive note with a target price of 88p which is over 4x the current price of 18.5p. So if we don't see a substantial rise fairly soon Shore Capital are going to look pretty incompetent.
Shore Capital value AMYT at 88p sp From Shore Capital research note.Amryt (AMYT)+ – Opportunity significantly de-risked; FV increased to 88p per share - House stock at 18.5pFollowing the recent (6th March) update on the AP101 trial design and the positive newsflow during December (the €20m EIB loan and the licensing of EU/MENA rights to an approved ultra-rare disease product) we see the Amryt investment case as significantly de-risked. The €10m EIB financing tranche, available immediately, significantly reduces the near-term financing overhang, with Amryt now able to fund itself through to the pivotal Phase 3 EB data in mid-2018F. Together with the opportunity for near-term revenues from Lojuxta (lomitapide) in select countries, we see Amryt as a compelling investment opportunity, offering exposure to a promising late-stage clinical candidate (AP101 / Episalvan in EB) as well as a pipeline of early stage (AP102 in acromegaly) and marketed (Lojuxta in HoFH) products. With the additional financing flexibility from the EIB facility, together with the Lojuxta marketing agreement offering near-term revenues as well as the opportunity for Amryt to build its commercialisation infrastructure, we have lowered our discount rate to a still conservative 20% (from 30% previously), reflecting the clinical risk associated with EB. Together with our updated forecasts, to reflect the addition of Lojuxta, our revised DCF fundamental valuation is c. GBp 88/share, corresponding to an equity value of c.£180m
Re: : Another Dodo i agree untra. hold tight, next 12 months determine if we were wise to invest here
Re: : Another Dodo Why keep changing the name? I would have thought that was pretty obvious! It was Fastnet oil & gas. It became Fastnet Equity when the oil & gas interests were ditched. It became Amryt Pharma following an RTO with a biotech. Seems perfectly logical to me!I think AMYT could prove to be an excellent investment over the next few years. Only time will tell if I'm correct.
Re: : Another Dodo Ramping again on SP blog.. state on hot stocks rockets ( £ 500 per year !!! )formerly fastnet equity , formerly fastnet ol and gas, formerly sterling gas, formerly hamilton partners .Why keep changing the name ???
info text and check out the interview as well[link]
Re: Deals You maybe right on this one. Fastnet had many patients suffering from the disappearing market value disease. Lets hope that Amryt can perform radical surgery on us patients leading to, "as the medical profession say" beneficial outcomes.
Deals Finally news of some good deals, I think this company is just getting started, hopefully more to come...A patient ex-Fastnet holder.